A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. Daily treatment with an oral dose of AOD9604 of 500 µg/kg body weight for 19 days reduced over 50% (15.8 ± 0.6 vs. 35.6 ± 0.8 g) body weight gain of the animals in comparison with the control. The adipose tissues of the AOD9604–treated animals were found to have an increase in lipolytic activity. In contrast to chronic treatment with intact hGH, chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity of the animals, as demonstrated with euglycemic clamp techniques. The results in the present study suggest that the analogue of the hGH lipolytic domain may have the potential to be developed into an orally usable and safe therapeutic agent for obesity.

Keywords:
Human growth hormone, Lipolytic domain, Obesity, Insulin resistance, Zucker (fa/fa) rats
1.
Issaksson OG, Eden S, Jansson JO: Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol 1985;47:483–499.
2.
Raben MS: Human growth hormone. Rect Progr Horm Res 1959;15:71–105.
3.
Raben MS, Hollenberg CH: Effect of GH on plasma fatty acids. J Clin Invest 1959;39:484–488.
4.
Goodman HM, Gorin E, Honeyman TW: Biochemical basis for the lipolytic activity of growth hormone; in Underwood LE (ed): Human Growth Hormone – Progress and Challenge. New York, Dekker, 1986, pp 75–111.
5.
Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R: Effect of recombinant hGH on metabolic indices: Body composition and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470–479.
6.
Papadakis MA, Grady D, Black D: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996;124:708–716.
7.
Baumann G: Growth hormone heterogeneity: Genes, isohormones, variants, and binding protein. Endocr Rev 1991;12:424–449.
8.
Wijaya E, Ng FM: Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes. Biochem Mol Biol Int 1993;31:543–552.
9.
Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P: Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol, in press.
10.
Barany G, Albericio F: Peptide synthesis for biotechnology in the 1990s; in Bond S (ed): Biotechnology International 1990/1991. London, Century Press, 1991, pp 155–163.
11.
Zucker LM, Zucker TF: Fatty, a new mutation in the rat. J Hered 1961;52:275–278.
12.
Andres R, Swerdloff R, Pzefsky T, Coleman D: Manual feedback technique for the control of blood glucose concentration; in Skeggs LT Jr (ed): Automation in Analytical Chemistry. New York, Mediad, 1966, pp 486–491.
13.
Kraegen EW, James DE, Bennett SP, Chisholm DJ: In vivo insulin sensitivity in the rat determined by euglycaemic clamp. Am J Physiol 1983;245:E1-E7.
14.
Chrétien M: Clinical relevance of convertases: Atherosclerosis, Alzheimer’s disease, obesity, diabetes and HIV. Clin Invest Med 1999;22:207 -211.
15.
Ng FM: The role of human growth hormone in diabetes mellitus – A new perspective. Exp Clin Endocrinol (Life Sci Adv) 1993;12:129–139.
16.
Lopez-Guajardo CC, Armstrong LS, Jordan L, Staten NR, Krivi GG, Martinez AO, Haro LS: Generation, characterization and utilization of anti-hGH 1–43 monoclonal antibodies in an ELISA. J Immunol Methods 1998;215:179–185.
17.
Jeoung DI, Allen DL, Guller S, Yen V, Sonenberg M: Mitogenic and receptor activities of human growth hormone 108–129. J Biol Chem 1993;268:22520–22524.
18.
Liberti JP: Isolation and somatomedin activity of bovine growth hormone fragment 87–124. Biochim Biophys Acta 1981;675:239–247.
19.
Wu ZM, Ng FM: Anti-lipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone. Biochem Mol Biol Int 1993;30:187–196.
20.
Natera SHA, Jiang WJ, Ng FM: Reduction of cumulative body weight gain and adipose tissue mass in obese mice: Response to chronic treatment with synthetic hGH 177–191. Biochem Mol Biol Int 1994;33:1011–1021.
21.
Strobl JS, Thomas MJ: Human growth hormone. Pharm Rev 1994;46:1–34.
22.
Richelsen B: Action of GH in adipose tissues. Horm Res 1997;48(suppl 5):105–110.
23.
Brummer RJM, Bengtsson B-A: The effect of growth hormone on body composition. Asia Pacific J Clin Nutr 1995;4:151–155.
24.
Holloway L, Butterfield G, Hintz RL, Gesundheit N, Marcus R: Effect of recombinant growth hormone on metabolic indices, body composition and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994;79:470–479.
25.
Papadakis MA, Grady D, Black D: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996;124:708–716.
26.
Jorgensen JOL, Vahl N, Hansen TB, Fisker S, Hagen C, Christiansen JS: Influence of growth hormone and androgens on body composition in adults. Horm Res 1996;45:94–98.
27.
Thompson PE, Lim N, Ede NJ, Ng FM, Rae ID, Hearn M: Structure and in vivo activity of hypoglycemic analogues of hGH 6–13. Drug Design Discovery 1995;13:55–72.
28.
Rowlinson SW, Waters MJ, Lewis UJ, Barnard R: Human growth hormone fragments 1–43 and 44–191: In vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems. Endocrinology 1996;137:265–273.
29.
Bray GA, Greenway FL: Current and potential drugs for treatment of Obesity. Endocr Rev 1999;20:805–875.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.